Q2 2026 Earnings Season for the Peptide-and-Obesity Big Three Opens Next Week With Merck Reporting Tuesday August 4, Eli Lilly Wednesday August 5, and Novo Nordisk Thursday August 6: Analyst Focus Areas Include Merck's LIPFENDRA (Enlicitide) FDA Approval Milestone One Week Old at Report Time, Eli Lilly's Foundayo (Orforglipron) First-Quarter-Out US Retail Sales, Zepbound Growth Versus the Wegovy Pill Franchise, and Novo Nordisk's Response to Analyst Concerns About 2027 Wegovy List Price Reset to $675 That Would Represent a 50% Cut From the Current Level
Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.